$1,382.75
Value $1.30T
LLY and SPRY stock compared: price, dividend, valuation and results, from SEC filings.
$1,382.75
Value $1.30T
$3.69
Value $366M
Eli Lilly and Company (LLY) has a market value of $1.30T and ARS Pharmaceuticals (SPRY) $366M. Over the last year, with dividends, LLY moved +36.2% and SPRY -49.6%. Dividend yield: LLY 0.46%, SPRY none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LLY$1.30T
SPRY$366M
LLY is 3,560 times SPRY
Revenue, 12 months
LLY$86.5B
SPRY$122M
LLY is 708 times SPRY
Net income, 12 months
LLY$27.6B
SPRY-$200M
Operating margin
LLY–
SPRY-161.5%
ROIC
LLY35.5%
SPRY-93.7%
129.2 points apart
P/E
LLY47.3
SPRY–
Dividend yield
LLY0.5%
SPRY0.0%
0.5 points apart
5-year return
LLY+452.8%
SPRY-56.6%
509.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LLY+452.8%
SPRY-56.6%
| Period | LLYWith dividends | SPRYWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +36.2%Price +35.3% | -49.6%Price -49.6% |
| 3 years since November 17, 2023 | +138.4%+33.6% a yearPrice +133.7% | -21.7%-7.8% a yearPrice -21.7% |
| 5 years since November 17, 2021 | +452.8%+40.8% a yearPrice +429.4% | -56.6%-15.4% a yearPrice -56.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LLYEli Lilly and CompanySPRYARS Pharmaceuticals
| Price | $1,382.75 | $3.69 |
|---|---|---|
| Market value | $1.30T | $366M |
| Enterprise value (EV) | $1.35T | $350M |
| P/E | 47.3 | – |
| P/E, 5-year median | 49.9 | – |
| P/B | 32.4 | – |
| EV/EBIT | 38.8 | – |
| Free cash flow yield | 1.5% | – |
| Revenue, 12 months | $86.5B | $122M |
|---|---|---|
| Net income, 12 months | $27.6B | -$200M |
| Free cash flow, 12 months | $19.7B | -$183M |
| Earnings per share, 12 months | $30.81 | -$2.02 |
| Revenue growth, year on year | 44.7% | -5.5% |
| Revenue growth a year, past | +21.6%over 5 years | +97.8%over 4 years |
| EPS growth a year, past | +27.6%over 5 years | – |
| Gross margin | 83.6% | – |
|---|---|---|
| Operating margin | – | -161.5% |
| Net margin | 31.9% | -163.6% |
| ROIC | 35.5% | -93.7% |
| ROE | 88.6% | -308.7% |
| Cash | $4.9B | $138M |
|---|---|---|
| Total debt | $49.5B | $122M |
| Net debt / EBITDA | 1.2 | – |
| Interest cover | 38.9× | – |
| Dividend yield | 0.5% | – |
|---|---|---|
| Dividend per share, 12 months | $6.34 | – |
| Dividend growth a year, past | +15.2%over 5 years | – |
| Buyback yield | 0.3% | – |
| Shareholder yield | 0.8% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.30T) is about 3,560.1 times ARS Pharmaceuticals ($366M), at today's prices.
Since November 17, 2021, LLY's price moved +429.4% and SPRY's -56.6%. With dividends: LLY +452.8% (+40.8% a year), SPRY -56.6% (-15.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.46% for Eli Lilly and Company and none for ARS Pharmaceuticals. Over the last twelve months they paid $6.34 and – per share.
Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -163.6% for ARS Pharmaceuticals, and the operating margin – and -161.5%. Revenue was $86.5B and $122M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.